phs000857
Primary ER-positive Breast Cancer Treated with Neoadjuvant Letrozole
These are tumor biopsies and corresponding normal samples from patients with early stage ER+/HER2- breast cancer who had received the aromatase inhibitor letrozole for 10-21 days prior to surgery.